Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay.
Programmed death-1 (PD-1) protein is a co-inhibitory receptor which negatively regulates immune cell activation and permits tumors to evade normal immune defense. Anti-PD-1 antibodies have been shown to restore immune cell activation and effector function-an exciting breakthrough in cancer immunotherapy. Recent reports have documented a soluble form of PD-1 (sPD-1) in the circulation of normal and disease state individuals. A clinical assay to quantify sPD-1 would contribute to the understanding of sPD-1-function and facilitate the development of anti-PD-1 drugs. Here, we report the development and validation of a sPD-1 protein assay. The assay validation followed the framework for full validation of a biotherapeutic pharmacokinetic assay. A purified recombinant human PD-1 protein was characterized extensively and was identified as the assay reference material which mimics the endogenous analyte in structure and function. The lower limit of quantitation (LLOQ) was determined to be 100 pg/mL, with a dynamic range spanning three logs to 10,000 pg/mL. The intra- and inter-assay imprecision were ≤15%, and the assay bias (percent deviation) was ≤10%. Potential matrix effects were investigated in sera from both normal healthy volunteers and selected cancer patients. Bulk-prepared frozen standards and pre-coated Streptavidin plates were used in the assay to ensure consistency in assay performance over time. This assay appears to specifically measure total sPD-1 protein since the human anti-PD-1 antibody, nivolumab, and the endogenous ligands of PD-1 protein, PDL-1 and PDL-2, do not interfere with the assay.
Bioanalytical Science-Biologics, Bristol-Myers Squibb, L4.016B, Route 206 & Province Line Rd, Princeton, New Jersey, 08543, USA, Yan.Ni@BMS.com.
Yan G
YG
Ni
Xiling
X
Yuan
John A
JA
Newitt
Jon E
JE
Peterson
Carol R
CR
Gleason
Jonathan
J
Haulenbeek
Rasa
R
Santockyte
Virginie
V
Lafont
Frank
F
Marsilio
Robert J
RJ
Neely
Binodh
B
DeSilva
Steven P
SP
Piccoli
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D001681:Biological Assay / Q000379:methods*; D016022:Case-Control Studies; D057809:HEK293 Cells; D006801:Humans; D057230:Limit of Detection; D009369:Neoplasms / Q000097:blood; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000032:analysis*; D011994:Recombinant Proteins / Q000032:analysis*
D000911:Antibodies, Monoclonal; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D011994:Recombinant Proteins; D000077594:Nivolumab